MET mutation

A clinical trial led by Dr. Xiuning Le shows promising results for tepotinib with an EGFR tyrosine kinase inhibitor in patients with EGFR mutant MET-altered non-small cell lung cancer (9070). https://t.co/rDyv1GQIvj @LeXiuning @ASCO #ASCO23 #LungCancer #EndCancer 4/4 (@MDAndersonNews)

#ASCO23 @ASCO Abs#9021 Tepotinib + osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification #INSIGHT2 ➡️122 pts received tepo + osi ➡️98 pts w/ FISH METAmp: ORR 43.9% ➡️31 pts with METamp by LBx: ORR 51.6% Poster Discussion @JoelNealMD @OncoAlert @EGFRResisters (@CharuAggarwalMD)

I mainly use in driver mutation or brain met population, but admittedly the OS data have been lacking overall (while PFS with TKI combo have been quite robust). Perfectly reasonable to give docetaxel alone here I feel and what I do most commonly outside trial (@PatelOncology)

Join us on 4/26 for a Lung Cancer Webinar with @HatimHusainMD @UCSDCancer #DrMassarelli @COHMedOnc @MNagasaka @UCIrvineHealth on the Treatment of other Targetable Mutations (MET/RET). Sponsored by @AstraZenecaUS Register at https://t.co/gpcEnZ4HlY (@MOASC_Office)

Randomized Trial of Tepotinib Plus Gefitinib Versus Chemotherapy in EGFR-Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis https://t.co/gqqy7M0Wb4 (@AndresFCardonaZ)

A patient of #NSCLC has progressed on Capmatinib and NGS shows MET mutation yet again. Should I try switching to Crizotinib or Cabozantinib?The patient is 75, PS-3. Comorbs- CKD 2, Diabetes @ns_chd @danieltanmd @SewantiLimaye @drvineetgovinda @oncologician @shaunak_3 (@Doc_Amarendra)

Telisotuzumab vedotin (Teliso-V, an ADC targeting Met) plus osimertinib @JSMO_official. An ORR of 50% was demonstrated in patients with EGFR-mutated, c-Met–overexpressing (≥25% tumor cells at 3+ staining intensity) NSCLC after progression on prior Osimertinib. #JSMO2023 #LCSM (@HHorinouchi)

Mutational Landscape of 1172 Pts w/ HR+, HER2- Met Breast Cancer Tx'd w/ CDK4/6 Inhibitors [Dec 2022] Shah et al. #SABCS22 https://t.co/il0kHWVY58 #bcsm #PrecisionMedicine @TempusLabs (@mtmdphd)

Tepotinib plus osimertinib is a promising combination in patients with osimertinib-pretreated, EGFR-mutated, MET amplified non­–small cell lung cancer. @JulienMazieres @myESMO #lcsm #ESMO2022 https://t.co/9qB70fm09t (@OncLive)

⭐️Exploring the Next Frontier in Non–Small-Cell Lung Cancer With High MET and Mutated Epidermal Growth Factor Receptor 🫁🎯🧬 @JCO_ASCO @DrRaviSalgia @OncoAlert https://t.co/4ELAxK7e1E (@VivekSubbiah)

Very helpful narrative review of #MET and its role in NSCLC @JTOonline. Covers approved and emerging agents. With MET, need to distinguish #METex14 mutations, MET amplification, and MET overexpression - as implications of each are quite different. #LCSM https://t.co/i6BZG8L7vT (@StephenVLiu)

Final Phase Ib TATTON: Osimertinib+ Savolitinib to Overcome Acquired MET-Mediated Resistance in EGFR Mutated MET-Amplified NSCLC. MET copy-number ≥10 and EGFRm circulating tumor DNA clearance predict better outcomes. #LCSM https://t.co/9O4k9BeqMw (@Tony_Calles)

BRCA reversion mutations are a significant mechanism of acquired resistance to Rucaparib in patients with BRCA1 or 2 mutated met castration-resistant #prostate #Cancer @EUplatinum @OncoAlert @AkashPatnaik7 @cdanicas @Uroweb @APCCC_Lugano @scserendipity1 https://t.co/Mgn77tRHIs (@DrYukselUrun)

IDH2 mutants are (in Yorkshire) weird. I had one (big, pleomorphic ugly-ass cells) that was IDH2mt, and co deleted. Was tempted to call it "pleomorphic oligodendroglioma" or similar. Another IDH2 mutant was an oligo harbouring a met. (@JRobinHighley)

Tepotinib outcomes as compared to prior therapies in met exon 14 skip mutation NSCLC @EgbertSmith25 #esmo22 (@oncologician)

This patient's lung cancer tumor acquired resistance mutations in MET codons D1228 and Y1230 and concomitantly was diagnosed with metastatic melanoma most likely the BRAF V600E mutation arises from those cells (being confirmed in tissue) (@GRecondoMD)

BEACON translational analyses shared by @skopetz @myESMO: subclonal MAPK pathway activation with multiple acquired alterations (RAS/BRAF mutations, MET amplification…) as the main escape mechanism to BRAF/EGFR+/-MEK inhibition in BRAF V600 mutated mCRC (@malkadav)

💯% agree. MET biology is complex. In addition, important to remind that not all MET mutations are exon 14 skipping (those that matters). #WCLC22 #LCSM (@Tony_Calles)

#ASCO22 Dr. @MatthewGKrebs presents update on CHRYSALIS from amivantamab in #MET exon 14 skip mutation NSCLC. While amivantamab is approved for #EGFRex20, this bispecific targets both EGFR and MET with an even higher affinity for MET (40 pM) than EGFR (1.4 nM). (@StephenVLiu)

.@Pradnya_PatilMD of @ClevelandClinic provides key takeaways on targeted therapy approaches for EGFR-, RET-, MET-, and KRAS-mutant advanced NSCLC, as well as frontline and second-line treatment of patients with SCLC #lcsm https://t.co/pURXVBwNrG (@OncLiveSOSS)

.@Pradnya_PatilMD , of @ClevelandClinic, targeted therapy approaches for EGFR-, RET-, MET-, and KRAS-mutant advanced NSCLC, as well as frontline and second-line treatment of patients with SCLC #lcsm https://t.co/U9RvqetwSs (@OncLiveSOSS)

Great dataset to examine impact of KRAS mutation status between 444 paired primary and brain met lung adenocarcinoma samples. 'Mutational profiles of primary pulmonary adenocarcinoma and paired brain metastases disclose the importance of KRAS mutations'. https://t.co/7nPP1GjBm2 (@cancerassassin1)

Update on tepotinib in #MET exon 14 mutant NSCLC from the phase II VISION trial @CCR_AACR, led by Dr. @LeXiuning. RR 45% (n=152), same in 1L vs previously treated. 5/7 with measurable brain metastases had partial intracranial response. #LCSM https://t.co/HMoitEmMBH (@StephenVLiu)

Yes patients w met BRAF mutant melanoma should get ipi + nivo and not PD1 mono. I would argue for the 1 mg/kg ipi regimen https://t.co/Ax6Aczm9uh (@jasonlukemd)

.@StephenVLiu, of @LombardiCancer, discussed the role of immunotherapy in locally advanced and advanced NSCLC, the challenges of navigating new targeted options in EGFR- and MET-mutated NSCLC, and the new standard of care for mesothelioma #lcsm https://t.co/S7ZuGM1Gec (@OncLiveSOSS)

Dr. @alexdrilon reviews #MET in NSCLC in #PTTO2021. Capmatinib and tepotinib now approved for METex14. Resistance can be mediated by decreased expression, MET kinase domain mutations, or off target mechanisms like EGFR and KRAS. Consider type switching as a strategy! #LCSM (@StephenVLiu)

@Pradnya_PatilMD, of @ClevelandClinic, provided key takeaways from an IPC meeting, which covered targeted therapy approaches for EGFR-, RET-, MET-, and KRAS-mutant advanced NSCLC and front- and second-line treatment of SCLC #lcsm https://t.co/H2noPQUmXO (@OncLiveSOSS)

Dr. @LudaBazhenovaMD helps navigate newer relevant mutations in NSCLC including #KRAS #MET #BRAF and #HER2. Each with a different biology and each with a different treatment plan. Great to see such progress! #CFS2021 #LCSM #LCAM @gotoPER (@StephenVLiu)

.@StephenVLiu discusses the role of immunotherapy in locally advanced and advanced NSCLC, the challenges of navigating new targeted options in EGFR- and MET-mutated NSCLC, and the new standard of care for mesothelioma. @LombardiCancer #lcsm https://t.co/xSLAeJMiD7 (@OncLive)

@StephenVLiu, of @LombardiCancer, discussed the role of immunotherapy in locally advanced and advanced NSCLC, the challenges of navigating new targeted options in EGFR- and MET-mutated NSCLC, and the new standard of care for mesothelioma #lcsm https://t.co/nzdMrXRBoa (@OncLiveSOSS)

You can interrogate met mutations many ways. I’m going to focus on met exon 14 skipping mutations (will be exclusive as you can have this and none other) says ⁦@benlevylungdoc⁩ ⁦@OncLiveSOSS⁩ #ipc with chair ⁦@StephenVLiu⁩ ⁦@LombardiCancer⁩ ⁦#lungcancer (@donnashort)

We know #MET exon 14 mutations are actionable in NSCLC with approvals of capmatinib and tepotinib. What's next? Dr. @benlevylungdoc reviews resistance to these agents and highlights promising activity with novel agents like amivantamab post TKI. Watch this space! #LCSM (@StephenVLiu)

The availability of targeted agents for pts w/ advanced NSCLC who harbor mutations in EGFR, RET, MET, & KRAS has led to improved outcomes & provided greater flexibility for treatment-naïve and pretreated populations @Pradnya_PatilMD @ClevelandClinic #lcsm https://t.co/jcG0sEnUIu (@OncLive)

Patil, discusses targeted therapy approaches for EGFR-, RET-, MET-, and KRAS-mutant advanced NSCLC, as well as frontline and second-line treatment of patients with SCLC @Pradnya_PatilMD @ClevelandClinic #lcsm https://t.co/izoGwuXpm6 (@OncLive)

#ESMO21 #MET can be dysregulated in many different ways. Dr. Pascale Tomasini highlights the difference between MET overexpression, amplification, mutation, fusion. MET also mediates resistance to other targets like #KRAS but with clonal heterogeneity, these can co-exist. #LCSM (@StephenVLiu)

#WCLC21 Dr. @AlexSpiraMDPhD presents data on amivantamab in #MET exon 14 mutation NSCLC. Amivantamab was approved for #EGFR exon 20 insertion NSCLC May 21, 2021. It is a bispecific antibody targeting EGFR and MET. This cohort of CHRYSALIS focused on METex14. #LCSM (@StephenVLiu)

#WCLC21 This cohort included 19 patients with #MET exon 14 skip mutation NSCLC (60% non-smoker, 40% smoker). 42% had prior MET targeted therapy and 21% were treatment naive. Safety data include high rate of infusion reactions but these are typically just with the first dose. (@StephenVLiu)

Advances in the Management of Thoracic Malignancies #ِAMTM Treatment of Stage IV NSCLC with other mutations (Met/Ret) Speaker: Dr. Christian Rolfo @ChristianRolfo The session is full but you can see the live broadcast here https://t.co/Zydpt2Zp4q (@Oncology_Events)

Demographics: 91% of pts with KRAS #G12C had nonsquamous histology. But in this report, 4.2% had squamous histology. So KRAS G12C can occur in squamous. So can other drivers (such as #MET exon 14 skip mutations). It's my practice to pursue NGS for all NSCLC - can't miss these. (@StephenVLiu)

Treatment advances for patients w/ NSCLC who harbor HER2, EGFR, KRAS, & MET mutations have set the stage for further research aimed at generating better treatments. @NickRohsMD @ipreeshagul @JSabari @sloan_kettering @nyulangone @MountSinaiNYC #lcsm https://t.co/vE5gwxidck (@OncLive)

#CIOT21 Dr. Juergen Wolf helps review #MET exon 14 skip mutations. Overall, capmatinib and tepotinib are comparable with similar efficacy, similar toxicity (edema, GI), and some signal in MET amplified NSCLC as well but differences in how they were studied. #LCSM @CIOT_21 (@StephenVLiu)

Indeed and if chemoIO neoadj + surgery results in MRD negative, then no need for adj anything, right? My take is that adj anything should be reserved for driver mutation + or incidental N+. That said my last met exon 14 patient who got chemoIO has 99% tumor kill. #ASCO21 #LCSM (@DoctorJSpicer)